Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda

Clinical Infectious Diseases

Volumn 47, Issue 9, 2008, Pages 1126-1134

  Temple, Beth ^a   Ayakaka, Irene ^b   Ogwang, Sam ^c   Nabanjja, Helen ^b   Kayes, Susan ^c   Nakubulwa, Susan ^a   Worodria, William ^d   Levin, Jonathan ^a   Joloba, Moses ^c,d   Okwera, Alphonse ^b,e   Eisenach, Kathleen D ^c,f   McNerney, Ruth ^h   Elliott, Alison M ^a,h   Smith, Peter G ^h   Mugerwa, Roy D ^b,d   Ellner, Jerrold J ^b,g   Jones López, Edward C ^b,g  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b MAKERERE UNIVERSITY   (Uganda)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^e MULAGO HOSPITAL   (Uganda)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ACID FAST BACTERIUM; ADULT; ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC TEST; DRUG SENSITIVITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPUTUM CULTURE; TREATMENT FAILURE; TUBERCULOSIS; UGANDA;

ADULT; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; UGANDA;

EID: 53349157182     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592252     Document Type: Article

References (42)

1. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug resistant tuberculosis. J Infect Dis 2006; 194:479-85.
2. Espinal MA, Kim SJ, Suarez PG, et al. Standard short course chemotherapy for drug resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537-45.
3. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
4. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
5. Raviglione M, Uplekar M. WHO's new stop TB strategy. Lancet 2006; 367: 952-5.
6. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2:10-5.
7. Mitchinson DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.Am Rev Respir Dis 1986; 133:423-30.
8. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus." BMJ 1998; 317:671-4.
9. Quy HT, Lan NT, Borgdorff MW, et al. Drug resistance among failure and relapse cases of TB: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003; 7:631-6.
10. Seung KJ, Gelmanova IE, Peremitin GG, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004; 39:1321-8.
11. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004; 8:31-8.
12. Cox HS, Niemann S, Ismailov G, et al. Risk of acquired drug resistance during short- course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis 2007; 44:1421-7.
13. Umubyeyi A, Shamputa IC, Rigouts L, et al. Evidence of 'amplifier effect' in pulmonary multidrug-resistant tuberculosis: report of three cases. Int J Infect Dis 2007; 11:508-12.
14. World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing. Geneva: WHO, 2007.
15. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs: World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344:1294-303.
16. Bretzel G, Aziz M, Wendl-Richter U, et al. Anti-tuberculosis drug resistance surveillance in Uganda 1996-1997. Int J Tuberc Lung Dis 1999; 3:810-5.
17. World Health Organization (WHO). Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Geneva: WHO, 2004: WHO/CDS/TB/2003.313.
18. Siddiqi S. Bactec 460 TB System: product and procedure manual. Maryland: Becton Dickinson, 1996.
19. Muhumuza J, Asiimwe BB, Kayes S, et al. Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. Int J Tuberc Lung Dis 2006; 10:1262-7.
20. Kent P, Kubica G. Public health mycobacteriology: a guide for the level III laboratory. US Department of Public Health and Human Service, Public Health Service. Atlanta: Centers for Disease Control and Prevention, 1985.
21. Van Embden JD, Cave MD, Crawford JT, et al. Strain identification of by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31:406-9.
22. World Health Organization. Rapid HIV tests: guidelines for use in HIV testing and counseling services in resource-constrained settings. 2004. Available at: http://www.who.int/hiv/pub/vct/rapidhivtests/en/. Accessed 21 January 2008.
23. World Health Organization (WHO)-International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world: third global report. Geneva: WHO, 2004.
24. Umubyeyi AN, Vandebriel G, Gasana M, et al. Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis 2007; 11:189-94.
25. Abate G, Miörner H, Ahmed O, et al. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Int J Tuberc Lung Dis 1998; 2:580-4.
26. World Health Organization (WHO). Anti-tuberculosis drug resistance in the world: 4th global report. Geneva: WHO, 2008:WHO/HTM/TB/2008.394.
27. Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis 2000; 4:481-4.
28. DeBarber AE, Mdluli K, Bosman M, et al. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. PNAS 2000; 97:9677-82.
29. Sevim T, Ataç G, Güngör G, et al. Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2002; 6:320-5.
30. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5:887-93.
31. Sharma SK, Turaga KK, Balamurugan A, et al. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect Genet Evol 2003; 3:183-8.
32. Kaplan G, Post FA, Moreira AL, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003; 71:7099-108.
33. Canetti G, Parrot R, Porven G, Le Lirzin M. Rifomycin levels in the lung and tuberculous lesions in man. Acta Tuberc Pneumol Belg 1969; 60:315-22.
34. Joloba ML, Whalen CC, Cave DM, et al. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda. East Afr Med J 2000; 77:111-5.
35. Kibiki GS, Mulder B, Dolmans WM, et al. M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania. BMC Microbiol 2007; 7:51.
36. Nelson LJ, Talbot EA, Mwasekaga MJ, et al. Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 2005; 366:488-90.
37. Weltman AC, Rose DN. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Arch Intern Med 1994; 154:2161-7.
38. Elliott AM, Namaambo K, Allen BW, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis 1993; 74:191-4.
39. Wallis RS, Perkins MD, Phillips M, et al. Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 2000; 161:1076-80.
40. Vásquez-Campos L, Asencios-Solis L, Leo-Hurtado E, et al. Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001. Int J Tuberc Lung Dis 2004; 8: 465-72.
41. Van Rie A, Victor TC, Richardson M, et al. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005; 172:636-42.
42. Behr MA. Tuberculosis due to multiple strains: a concern for the patient? A concern for tuberculosis control? Am J Respir Crit Care Med 2004; 169:554-5.